LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China
-- LIB Therapeutics to receive up to $325 million in upfront and milestone payments in addition to royalties -- Hasten...




















